GLORIA

GEOMAR Library Ocean Research Information Access

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 2015-2019  (2)
  • 1990-1994  (1)
  • 1
    ISSN: 1590-3478
    Keywords: Brain tumors ; viral genomic sequences ; herpes simplex virus ; simian virus 40 ; adenovirus type 2 ; DNA hybridization
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Sommario Poco si sa su oncogenesi dei tumori cerebrali. Si pensa che i virus siano coinvolti in alcune malattie neurologiche e la presenza di sottofrazioni di DNA virale è stata riportata in varie cirkostanze e l'oncogenicità di alcuni virus è stata dimostrata in animali da esperimento. Inoltre la scoperta di omologia tra gli oncogeni retrovirali e i normali geni cellulari ha stimolato la ricerca sulla responsabilità virale dell'oncogenesi. Gli Autori hanno sistematicamente esaminato 39 tumori cerebrali usando la ibridizzazione con DNA di 3 virus coinvolti in malattie neurologiche: quello dell'herpes simplex (HSV), il virus 40 (SV40) e l'adenovirus tipo 2 (Ad2). Non si è trovata omologia tra i DNA del materiale esaminato e il DNA virale. Sono stati allora comparati questi risultati negativi con quelli positivi di altri Autori riferendosi soprattutto alla possibilità di una ibridizzazione non specifica che può giustificare i risultati positivi riportati. Questa ricerca negativa può essere interpretata sia come un'assenza di coinvolgimento dei tre virus investigati nella oncogenesi dei tumori cerebrali, sia come espressione di una disposizione delle sequenze virali nel genoma ospite con conseguente prevenzione della ibridizzazione, come è stato supposto avvenga durante le fasi di latenza del virus herpetico.
    Notes: Abstract Little is known about oncogenesis in brain tumors. Viruses are thought to be involved in some neurological diseases, the presence of subfractions of viral DNA has been reportedin various circumstances and the oncogenicity of some viruses has been demonstrated in animal experiments. The discovery of homologies between retroviral ancogenes and normal cellular genes (proto-oncogenes) has stimulated once again the search for viral responsability in oncogenesis. Having a large bank of tumor material available, we systematically examined 39 brain tumors usign Southern blot hybridization with DNAs of three viruses, known to be involved in neurological diseases: herpes simplex virus (HSV), simian virus 40 (SV40) and adenovirus type 2 (Ad 2). We detected no homology between the DNAs of the examined material and the viral DNA probes. We compare these negative results with those of other published studies and discuss the experimental conditions, with special reference to the possibility of non-specific hybridization, which could account for the positive results reported. The present negative results could be interpreted either as absence of involvement of the three investigated viruse in brain tumor oncogenesis, or an indirect involvement through a hit-and-run mechanism or a highly dispersed state of the viral sequences among the host genome, which would prevent hybridization with the probe, as it has been supposed to be the case during the latency phase of herpes virus.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Publication Date: 2017-10-14
    Description: Purpose: Glioblastoma (GBM) is the most common and malignant form of primary human brain tumor in adults, with an average survival at diagnosis of 18 months. Metabolism is a new attractive therapeutic target in cancer; however, little is known about metabolic heterogeneity and plasticity within GBM tumors. We therefore aimed to investigate metabolic phenotyping of primary cultures in the context of molecular tumor heterogeneity to provide a proof of concept for personalized metabolic targeting of GBM. Experimental Design: We have analyzed extensively several primary GBM cultures using transcriptomics, metabolic phenotyping assays, and mitochondrial respirometry. Results: We found that metabolic phenotyping clearly identifies 2 clusters, GLN High and GLN Low , mainly based on metabolic plasticity and glutamine (GLN) utilization. Inhibition of glutamine metabolism slows the in vitro and in vivo growth of GLN High GBM cultures despite metabolic adaptation to nutrient availability, in particular by increasing pyruvate shuttling into mitochondria. Furthermore, phenotypic and molecular analyses show that highly proliferative GLN High cultures are CD133 neg and display a mesenchymal signature in contrast to CD133 pos GLN Low GBM cells. Conclusions: Our results show that metabolic phenotyping identified an essential metabolic pathway in a GBM cell subtype, and provide a proof of concept for theranostic metabolic targeting. Clin Cancer Res; 23(20); 6292–304. ©2017 AACR .
    Print ISSN: 1078-0432
    Electronic ISSN: 1557-3265
    Topics: Medicine
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Publication Date: 2016-01-23
    Description: Background Subcutaneous (s.c.) administration of bortezomib is the most widely used route of administration for the treatment of patients with multiple myeloma. No study has as yet prospectively evaluated home versus hospital administration of s.c. bortezomib with respect to patient preference and cost. Patients and methods In this prospective trial, myeloma patients received the first administration of s.c. bortezomib of each cycle in the outpatient unit of the Department of Hematology. When possible, all subsequent doses of bortezomib within each cycle were provided at home. A cost analysis was carried out to compare the average cost of an injection of bortezomib in the outpatient unit and at home. In order to compare hospital and home administration of bortezomib for preference and satisfaction, patients had to complete 2 simple questionnaires analyzing 16 criteria, such as quality of life, well-being, social life, satisfaction, safety, quality of care, the reduction in personal transportation time, and personal anxiety. Each item was analyzed using a Likert scale. Results Fifty patients were studied. Overall, a total of 1043 s.c. injections of bortezomib were carried out, 655 (62.8%) at home, and 388 (35.2%) in the outpatient unit. The cost analysis showed that the total cost of one s.c. injection of bortezomib in the outpatient unit was 1510.09 versus 1224.57 for the home administration, which represents a reduction of 285.52, i.e. 20% of the cost of the hospital administration. The evaluation of patient preference and satisfaction showed that home administration improved the quality of life in 84% of the patients, increased well-being in 78%, and improved the activities of daily living in 72% of the cases. Overall, 98% of the patients noted their preference for home administration over the hospital administration of bortezomib. Conclusion Home administration of s.c. bortezomib is cost-effective and is preferred by myeloma patients compared with hospital administration.
    Print ISSN: 0923-7534
    Electronic ISSN: 1569-8041
    Topics: Medicine
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...